166 related articles for article (PubMed ID: 15572595)
1. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Quintas-Cardama A; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Rios MB; Hayes K; Glassman A; Bekele BN; Zhou X; Cortes J
Blood; 2005 Mar; 105(6):2281-6. PubMed ID: 15572595
[TBL] [Abstract][Full Text] [Related]
2. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.
Huntly BJ; Guilhot F; Reid AG; Vassiliou G; Hennig E; Franke C; Byrne J; Brizard A; Niederwieser D; Freeman-Edward J; Cuthbert G; Bown N; Clark RE; Nacheva EP; Green AR; Deininger MW
Blood; 2003 Sep; 102(6):2205-12. PubMed ID: 12750153
[TBL] [Abstract][Full Text] [Related]
3. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
Castagnetti F; Testoni N; Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A; Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
J Clin Oncol; 2010 Jun; 28(16):2748-54. PubMed ID: 20439635
[TBL] [Abstract][Full Text] [Related]
4. Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.
Bennour A; Ouahchi I; Ben Youssef Y; Zaier M; Laatiri MA; Harrabi I; Meddeb B; Elloumi M; Khelif A; Saad A; Sennana H
Med Oncol; 2012 Jun; 29(2):1151-60. PubMed ID: 21461967
[TBL] [Abstract][Full Text] [Related]
5. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cortes JE; Talpaz M; Giles F; O'Brien S; Rios MB; Shan J; Garcia-Manero G; Faderl S; Thomas DA; Wierda W; Ferrajoli A; Jeha S; Kantarjian HM
Blood; 2003 May; 101(10):3794-800. PubMed ID: 12560227
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Jabbour E; Kantarjian HM; Jones D; Shan J; O'Brien S; Reddy N; Wierda WG; Faderl S; Garcia-Manero G; Verstovsek S; Rios MB; Cortes J
Blood; 2009 Mar; 113(10):2154-60. PubMed ID: 19060245
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Cervera E; Candelaria M; López-Navarro O; Labardini J; Gonzalez-Fierro A; Taja-Chayeb L; Cortes J; Gordillo-Bastidas D; Dueñas-González A
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):207-12. PubMed ID: 22420986
[TBL] [Abstract][Full Text] [Related]
9. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Quintás-Cardama A; Kantarjian H; Shan J; Jabbour E; Abruzzo LV; Verstovsek S; Garcia-Manero G; O'Brien S; Cortes J
Cancer; 2011 Nov; 117(22):5085-93. PubMed ID: 21523765
[TBL] [Abstract][Full Text] [Related]
11. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Rege Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G;
Blood; 2009 Apr; 113(15):3428-34. PubMed ID: 19211938
[TBL] [Abstract][Full Text] [Related]
12. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
13. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
14. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.
Matsuo E; Miyazaki Y; Tsutsumi C; Inoue Y; Yamasaki R; Hata T; Fukushima T; Tsushima H; Imanishi D; Imaizumi Y; Iwanaga M; Sakai M; Ando K; Sawayama Y; Ogawa D; Kawaguchi Y; Nagai K; Tsukasaki K; Ikeda S; Moriuchi Y; Yoshida S; Honda M; Taguchi J; Onimaru Y; Tsuchiya T; Tawara M; Atogami S; Yamamura M; Soda H; Yoshida Y; Matsuo Y; Nonaka H; Joh T; Takasaki Y; Kawasaki C; Momita S; Jinnai I; Kuriyama K; Tomonaga M
Int J Hematol; 2007 Feb; 85(2):132-9. PubMed ID: 17321991
[TBL] [Abstract][Full Text] [Related]
15. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; O'Brien S; Jones D; Giles F; Garcia-Manero G; Faderl S; Ravandi F; Rios MB; Shan J; Cortes J
Blood; 2006 Sep; 108(6):1835-40. PubMed ID: 16709931
[TBL] [Abstract][Full Text] [Related]
16. Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba.
Morán VP; Baute RG; Facundo JC; Ramírez PH; Núñez AA; Martínez EE; Cabrera OM; Padrón CH; Otero AG; Uría JC; Estrada EE; Díaz RM; Virgil AM; Sánchez KL; Cabeza AH
MEDICC Rev; 2011 Jan; 13(1):35-40. PubMed ID: 21273957
[TBL] [Abstract][Full Text] [Related]
17. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
19. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]